Mode
Text Size
Log in / Sign up

CircRNAs demonstrate high diagnostic accuracy for osteoporosis with an AUC of 0.91New blood markers show promise in detecting bone loss

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that circRNAs show high diagnostic accuracy for osteoporosis but must be used as adjunctive rather than stand-alone tests.

This meta-analysis synthesized data from 14 independent studies involving 801 patients with osteoporosis and 640 non-osteoporosis controls to evaluate the diagnostic accuracy of circRNAs or circRNA panels. The primary finding is that circRNAs show high diagnostic performance, including an area under the curve (AUC) of 0.91, a sensitivity of 0.87, and a specificity of 0.79. Other reported metrics include a positive likelihood ratio (PLR) of 4.24, a negative likelihood ratio (NLR) of 0.16, and a diagnostic odds ratio (DOR) of 26.24.

The authors note that while these results are robust according to sensitivity analyses and showed no significant publication bias, circRNAs are not stand-alone diagnostic tests. The correlation between circRNA expression and osteoporosis status is an association rather than a proven cause.

Clinically, circRNAs may serve as promising non-invasive biomarkers for screening and risk stratification. However, they should be utilized as adjunctive tools rather than primary diagnostics. Further large-scale prospective studies are required before these markers can be integrated into routine clinical practice.

How this fits prior evidence

This meta-analysis addresses a gap in the identification of non-invasive biomarkers for osteoporosis. It complements existing research on risk stratification and management trends mentioned in previous coverage. While other findings have explored pharmacological interventions like curcumin or gut microbiota to influence bone metabolism, this study focuses specifically on the diagnostic accuracy of circRNAs as potential screening tools.

Living with osteoporosis means dealing with bones that become fragile and break easily. Finding a way to catch this condition early is vital for keeping people active and safe. New research looks at a specific type of genetic material called circRNAs as a tool to help doctors identify who is at risk.

Researchers looked at data from 14 different studies involving over 800 patients with osteoporosis and 640 healthy controls. They found that these circRNA markers had high accuracy in identifying the condition, with a diagnostic score of 0.91. This means the markers were very effective at distinguishing between healthy bone and bone loss.

While these results are promising, it is important to know that these tests are not meant to work alone. They are intended to be used alongside current methods like bone density scans. More large-scale studies are still needed before these tests can become a standard part of routine doctor visits.

What this means for you:
CircRNA markers show high accuracy in identifying osteoporosis but must be used alongside other tests, not alone.

Common questions

How accurate are these new circRNA tests?

The study found these markers had a high accuracy score of 0.91. They also showed a sensitivity of 0.87 and a specificity of 0.79, which helps doctors better identify patients with osteoporosis compared to those without the condition.

Can this test replace my current bone density scan?

No, these tests are not stand-alone diagnostic tools. They are intended to be used as extra tools to help doctors screen and group patients by risk, rather than replacing existing methods like bone mineral density scans.

Is this test ready for use in every doctor's office?

Not yet. While the results are promising, more large-scale studies are needed before these tests can be used as a routine part of clinical care. You should talk to your doctor about current screening options.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BackgroundWith population ageing, osteoporosis (OP) is increasing worldwide. Circular RNAs (circRNAs) show aberrant expression in OP and may serve as non-invasive biomarkers, but their overall diagnostic performance and sources of heterogeneity remain unclear. This study aimed to systematically evaluate the diagnostic accuracy of circRNAs as potential non-invasive biomarkers for OP and to explore sources of heterogeneity.MethodsPubMed, Embase, Web of Science, the Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang, and VIP were searched from inception to 25 November 2025. Studies evaluating circRNAs or circRNA panels for osteoporosis (OP) using DXA-derived bone mineral density (BMD) as the reference standard were included. Methodological quality was assessed using QUADAS-2. A bivariate random-effects model was used to pool sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratios, and the area under the summary receiver operating characteristic curve. Subgroup analyses, meta-regression, sensitivity analyses, and Deeks’ funnel plot asymmetry test were performed.Results12 articles comprising 14 independent studies (801 OP patients and 640 non-OP controls) were included. The pooled SEN was 0.87 and SPE was 0.79; PLR and NLR were 4.24 and 0.16, respectively, with a DOR of 26.24 and an AUC of 0.91, indicating good overall discriminatory ability. Spearman correlation (r = −0.169, P = 0.563) suggested no obvious threshold effect. Subgroup analyses and meta-regression showed that diagnostic performance tended to be better in studies enrolling postmenopausal OP patients, with mean age < 65 years, larger sample sizes, non-serum/plasma samples (peripheral blood mononuclear cells or exosomes), and down-regulated circRNAs. Deeks’ funnel plot indicated no significant publication bias, and sensitivity analyses suggested that the main findings were robust.ConclusionCircRNAs demonstrate favorable diagnostic accuracy for osteoporosis and may serve as promising non-invasive biomarkers for screening and risk stratification. Current evidence supports their role as adjunctive tools that complement, rather than replace, DXA-derived bone mineral density assessment and traditional clinical risk factor evaluation. However, they should not be considered stand-alone diagnostic tests. Further large-scale prospective studies are required before routine clinical application can be recommended.Systematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420251240922.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.